Brian Pollok

Brian Pollok

Geen lopende functies

Health Technology
Consumer Services
Electronic Technology

Profiel

Brian A.
Pollok
was the founder of Neoantigenics, Inc. (2012) and Ansata Therapeutics, Inc. (2002), where he held the titles of Chief Executive Officer & Director and Senior Vice President-Research & Development, respectively.
Mr. Pollok is also the founder of Propagenix, Inc. Mr. Pollok's former jobs include Director at University of Virginia Licensing & Ventures Group, Vice President-Discovery Biology at Aurora Biosciences Corp.
(1997-2002), Chief Scientific Officer at Invitrogen Corp., President at American Type Culture Collection (2011-2012), Principal at Wake Forest University (1987-1993), Senior Research Investigator at Pfizer Central Research (1993-1997), and Chief Scientific Officer & Head-Global Research at Life Technologies Corp.
(2008-2011).
Mr. Pollok's education history includes undergraduate and graduate degrees from the University of Virginia and a doctorate degree from The University of Alabama (1983).

Eerdere bekende functies van Brian Pollok

BedrijvenFunctieEinde
Oprichter 01-01-2024
President 01-07-2012
Hoofd Techniek/Wetenschap/O&O 01-04-2011
Corporate Officer/Principal 01-07-2002
Pfizer Central Research Corporate Officer/Principal 31-12-1997
Ervaring van Brian Pollok in detail bekijken

Opleiding van Brian Pollok

University of Virginia Graduate Degree
The University of Alabama Doctorate Degree

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Ervaring van Brian Pollok in detail bekijken

Connecties

100 +

Eerstegraads connecties

12

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Persoonlijk netwerk weergeven

Verwante bedrijven

Bedrijven in privébezit9

Health Technology

Electronic Technology

Health Technology

Health Technology

Health Technology

Health Technology

Pfizer Central Research

Commercial Services

Finance

Zie bedrijfsconnecties
  1. Beurs
  2. Insiders
  3. Brian Pollok
-40 % Aanbod van beperkte duur: onze abonnementen leiden je naar de beste beleggingen van morgen.
PROFITEER NU